drugset / Trial / NCT02912494

A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)

NCT02912494

Double-blind

Summary

The purpose of this study is to investigate the equivalence of JR-131 to Darbepoetin alfa and evaluate the safety of JR-131 in renal anemia patients with chronic kidney disease (CKD).

Timeline

Start
2016-09
Primary completion
2017-09
Completion
2017-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Darbepoetin alfa Protein / enzyme biologic
Subject JR-131 Unknown

Indications